This content is current only at the time of printing. This document was printed on 25 February 2020. A current copy is located at https://apvma.gov.au/node/49836
You are here
Evaluation of the new active constituent d-cloprostenol in the product DALMAZIN
This consultation closed on 16 July 2019.
The APVMA is considering an application for approval of the new active constituent d-cloprostenol and registration of the product DALMAZIN, containing 75 micrograms/mL d-cloprostenol. The product will be used for the induction of oestrus in mares, synchronisation or induction of oestrus in cows and induction of parturition in cows and sows. The product is also indicated for the expulsion of mummified foetus, induction of abortion, ovarian dysfunction (persistent corpus luteum, luteal cyst) treatment, endometritis/pyometra and delayed uterine involution treatment in cows.
We invite comment from 18 June 2019 to 16 July 2019 on whether approval of the active constituent and registration of the product should be granted.
The APVMA is able to consider comments relating to the legislative grounds, including:
- chemistry and manufacture
- occupational health and safety
- public health
- environmental safety
- residues in food
- efficacy and target animal safety
Download the public release summary on the evaluation of DALMAZIN.
For more information see page 18, APVMA Gazette No. 12, 18 June 2019
Please send your written submission by email, post or fax to:
Case Management and Administration Unit
Australian Pesticides and Veterinary Medicines Authority
PO Box 6182
Kingston ACT 2604
Phone: +61 2 6210 4701
Fax: +61 2 6210 4721